Solid pharmaceutical composition for oral use in the form of tablets comprising: - a first solid pharmaceutical formulation for oral use in the form of at least one microcompressed, the microcompressed having a size in a range of 2 to 4 mm, and being constituted by a core of at least one precursor salt of the Krebs cycle as an active ingredient, and by a coating comprising at least one coating agent, the precursor salt of the Krebs cycle being selected from smokers, malate, citrates, alpha-ketoglutarate, succinyl Coenzyme A , succinates and oxaloacetate, and - a second pharmaceutical formulation for oral use in the form of at least one mini-tablet, the mini-tablet having a size in a range of 2 to 25 mm, and the mini-tablet consisting of a core comprising at least one bicarbonate salt as active ingredient and at least one hydrophilic extended release matrix, and by a coating that it includes at least one coating agent, where the in vitro dissolution of the second formulation in a pH-buffered dissolution medium in a range between 1.3 and 7, with a type 2 dissolution apparatus, according to the European Pharmacopoeia (Ph . Eur.) 2.9.3 "Dissolution test of solid forms" is produced according to a pH independent kinetics.Composición farmacéutica sólida para uso oral en forma de comprimidos que comprende: - una primera formulación farmacéutica sólida para uso oral en forma de al menos un microcomprimido, teniendo el microcomprimido un tamaño comprendido en un intervalo de 2 a 4 mm, y estando constituido por un núcleo de al menos una sal precursora del ciclo de Krebs como principio activo, y por un revestimiento que comprende al menos un agente de revestimiento, seleccionándose la sal precursora del ciclo de Krebs entre fumaratos, malatos, citratos, alfa-cetoglutarato, succinil Coenzima A, succinatos y oxaloacetato, y - una segunda formulación farmacéutica para uso oral en forma de al menos un minicomprimido, teniendo el minicomprimido un tamaño comprendido en un intervalo
